TW201940502A - 衍生自ＡｃｔＲＩＩＢ的變體與其用途 - Google Patents

Info

Publication number

TW201940502A

TW201940502A TW108124322A TW108124322A TW201940502A TW 201940502 A TW201940502 A TW 201940502A TW 108124322 A TW108124322 A TW 108124322A TW 108124322 A TW108124322 A TW 108124322A TW 201940502 A TW201940502 A TW 201940502A

Authority

TW

Taiwan

Prior art keywords

actriib

protein

polypeptide

sequence

seq

Prior art date

2007-02-02

Links

• Espacenet
• Global Dossier
• Discuss

• 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title abstract description 6
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 303
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 290
• 229920001184 polypeptide Polymers 0.000 claims description 282
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 238000000034 method Methods 0.000 abstract description 90
• 239000003446 ligand Substances 0.000 abstract description 86
• 230000000694 effects Effects 0.000 abstract description 75
• 210000003205 muscle Anatomy 0.000 abstract description 74
• 150000001875 compounds Chemical class 0.000 abstract description 67
• 239000000203 mixture Substances 0.000 abstract description 51
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 42
• 210000001519 tissue Anatomy 0.000 abstract description 41
• 210000000988 bone and bone Anatomy 0.000 abstract description 33
• 201000010099 disease Diseases 0.000 abstract description 25
• 210000000845 cartilage Anatomy 0.000 abstract description 19
• 230000002159 abnormal effect Effects 0.000 abstract description 14
• 230000012010 growth Effects 0.000 abstract description 13
• 238000012216 screening Methods 0.000 abstract description 9
• 230000002401 inhibitory effect Effects 0.000 abstract description 8
• 230000001537 neural effect Effects 0.000 abstract description 4
• 230000001737 promoting effect Effects 0.000 abstract description 4
• 108090000623 proteins and genes Proteins 0.000 description 150
• 235000018102 proteins Nutrition 0.000 description 123
• 102000004169 proteins and genes Human genes 0.000 description 123
• 210000004027 cell Anatomy 0.000 description 96
• 230000027455 binding Effects 0.000 description 95
• 235000001014 amino acid Nutrition 0.000 description 82
• 229940024606 amino acid Drugs 0.000 description 78
• 150000001413 amino acids Chemical class 0.000 description 77
• 230000035772 mutation Effects 0.000 description 60
• 108010059616 Activins Proteins 0.000 description 58
• 239000000488 activin Substances 0.000 description 58
• 102100026818 Inhibin beta E chain Human genes 0.000 description 57
• 241000699670 Mus sp. Species 0.000 description 53
• 108020001507 fusion proteins Proteins 0.000 description 46
• 102000037865 fusion proteins Human genes 0.000 description 46
• 238000012360 testing method Methods 0.000 description 41
• 150000007523 nucleic acids Chemical class 0.000 description 34
• 241000282414 Homo sapiens Species 0.000 description 32
• 230000004927 fusion Effects 0.000 description 31
• 102000005962 receptors Human genes 0.000 description 31
• 108020003175 receptors Proteins 0.000 description 31
• 230000001965 increasing effect Effects 0.000 description 29
• 239000013598 vector Substances 0.000 description 29
• 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 28
• 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 27
• 230000014509 gene expression Effects 0.000 description 27
• 102000039446 nucleic acids Human genes 0.000 description 26
• 108020004707 nucleic acids Proteins 0.000 description 26
• 238000011282 treatment Methods 0.000 description 26
• 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 25
• 241001529936 Murinae Species 0.000 description 25
• 102000045412 human ACVR2B Human genes 0.000 description 25
• 238000003556 assay Methods 0.000 description 24
• 108020001756 ligand binding domains Proteins 0.000 description 24
• 102220578642 Chorion-specific transcription factor GCMb_K74M_mutation Human genes 0.000 description 23
• 206010028980 Neoplasm Diseases 0.000 description 23
• 125000003275 alpha amino acid group Chemical group 0.000 description 23
• 201000006938 muscular dystrophy Diseases 0.000 description 23
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 22
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 22
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 22
• 229940112869 bone morphogenetic protein Drugs 0.000 description 22
• 239000003795 chemical substances by application Substances 0.000 description 22
• 239000012634 fragment Substances 0.000 description 22
• 208000008589 Obesity Diseases 0.000 description 21
• 239000003814 drug Substances 0.000 description 21
• 108010023082 activin A Proteins 0.000 description 20
• 235000020824 obesity Nutrition 0.000 description 20
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 19
• 208000001132 Osteoporosis Diseases 0.000 description 18
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
• 239000003925 fat Substances 0.000 description 17
• 235000019197 fats Nutrition 0.000 description 17
• 108020004414 DNA Proteins 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 16
• 208000035475 disorder Diseases 0.000 description 16
• 230000013595 glycosylation Effects 0.000 description 16
• 238000006206 glycosylation reaction Methods 0.000 description 16
• 238000001727 in vivo Methods 0.000 description 16
• 230000002829 reductive effect Effects 0.000 description 16
• 230000001225 therapeutic effect Effects 0.000 description 15
• 239000003981 vehicle Substances 0.000 description 15
• 230000019491 signal transduction Effects 0.000 description 14
• 206010006895 Cachexia Diseases 0.000 description 13
• 206010017076 Fracture Diseases 0.000 description 13
• 125000000539 amino acid group Chemical group 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 230000005764 inhibitory process Effects 0.000 description 13
• 239000002773 nucleotide Substances 0.000 description 13
• 125000003729 nucleotide group Chemical group 0.000 description 13
• 210000002706 plastid Anatomy 0.000 description 13
• 108091033319 polynucleotide Proteins 0.000 description 13
• 102000040430 polynucleotide Human genes 0.000 description 13
• 239000002157 polynucleotide Substances 0.000 description 13
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 description 12
• 108010076504 Protein Sorting Signals Proteins 0.000 description 12
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 12
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 12
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
• 230000001105 regulatory effect Effects 0.000 description 12
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 12
• 241000282412 Homo Species 0.000 description 11
• 201000011510 cancer Diseases 0.000 description 11
• 230000008859 change Effects 0.000 description 11
• 238000004519 manufacturing process Methods 0.000 description 11
• 210000002027 skeletal muscle Anatomy 0.000 description 11
• 210000001789 adipocyte Anatomy 0.000 description 10
• 239000000427 antigen Substances 0.000 description 10
• 108091007433 antigens Proteins 0.000 description 10
• 102000036639 antigens Human genes 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 238000000423 cell based assay Methods 0.000 description 10
• 230000003993 interaction Effects 0.000 description 10
• 239000002243 precursor Substances 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 208000011580 syndromic disease Diseases 0.000 description 10
• 230000008467 tissue growth Effects 0.000 description 10
• 201000006935 Becker muscular dystrophy Diseases 0.000 description 9
• 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 description 9
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
• 206010028289 Muscle atrophy Diseases 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 241000269370 Xenopus <genus> Species 0.000 description 9
• -1 acetamidine Amino acids Chemical class 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000004069 differentiation Effects 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 210000003527 eukaryotic cell Anatomy 0.000 description 9
• 239000002502 liposome Substances 0.000 description 9
• 230000004048 modification Effects 0.000 description 9
• 238000012986 modification Methods 0.000 description 9
• 150000003904 phospholipids Chemical class 0.000 description 9
• 230000035755 proliferation Effects 0.000 description 9
• 230000011664 signaling Effects 0.000 description 9
• 102000014914 Carrier Proteins Human genes 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 8
• 210000000577 adipose tissue Anatomy 0.000 description 8
• 108091008324 binding proteins Proteins 0.000 description 8
• 239000013604 expression vector Substances 0.000 description 8
• 239000003112 inhibitor Substances 0.000 description 8
• 238000010172 mouse model Methods 0.000 description 8
• 230000037257 muscle growth Effects 0.000 description 8
• 201000000585 muscular atrophy Diseases 0.000 description 8
• 210000002569 neuron Anatomy 0.000 description 8
• 230000001177 retroviral effect Effects 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 7
• 108010056852 Myostatin Proteins 0.000 description 7
• 230000004988 N-glycosylation Effects 0.000 description 7
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
• 230000002378 acidificating effect Effects 0.000 description 7
• 208000022531 anorexia Diseases 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 150000001720 carbohydrates Chemical group 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 206010061428 decreased appetite Diseases 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 235000009200 high fat diet Nutrition 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 102220479051 CD59 glycoprotein_L79D_mutation Human genes 0.000 description 6
• 102220525561 Coiled-coil domain-containing protein 200_A24N_mutation Human genes 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 108010070675 Glutathione transferase Proteins 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 6
• 102000004877 Insulin Human genes 0.000 description 6
• 108090001061 Insulin Proteins 0.000 description 6
• 108060008487 Myosin Proteins 0.000 description 6
• 102220542870 Presenilins-associated rhomboid-like protein, mitochondrial_L79E_mutation Human genes 0.000 description 6
• 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 6
• 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 235000018417 cysteine Nutrition 0.000 description 6
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
• 230000007547 defect Effects 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 235000011187 glycerol Nutrition 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 229940125396 insulin Drugs 0.000 description 6
• 150000002632 lipids Chemical group 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 238000013116 obese mouse model Methods 0.000 description 6
• 230000011164 ossification Effects 0.000 description 6
• 210000000963 osteoblast Anatomy 0.000 description 6
• 239000000843 powder Substances 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 210000001236 prokaryotic cell Anatomy 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• 208000016261 weight loss Diseases 0.000 description 6
• 230000004580 weight loss Effects 0.000 description 6
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
• 208000010392 Bone Fractures Diseases 0.000 description 5
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 241000283984 Rodentia Species 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
• 239000004473 Threonine Substances 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 235000003704 aspartic acid Nutrition 0.000 description 5
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
• 230000022159 cartilage development Effects 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 230000001086 cytosolic effect Effects 0.000 description 5
• 229960003957 dexamethasone Drugs 0.000 description 5
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
• 229940028334 follicle stimulating hormone Drugs 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 230000002163 immunogen Effects 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 210000000663 muscle cell Anatomy 0.000 description 5
• 230000003387 muscular Effects 0.000 description 5
• 208000018360 neuromuscular disease Diseases 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 230000008439 repair process Effects 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 102220638160 Arylamine N-acetyltransferase 1_R64K_mutation Human genes 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 206010065687 Bone loss Diseases 0.000 description 4
• 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 4
• 108091026890 Coding region Proteins 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 108060003951 Immunoglobulin Proteins 0.000 description 4
• 206010022489 Insulin Resistance Diseases 0.000 description 4
• 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 4
• 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 4
• 208000029578 Muscle disease Diseases 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 102220496976 Platelet-activating factor acetylhydrolase 2, cytoplasmic_L79A_mutation Human genes 0.000 description 4
• 239000004365 Protease Substances 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• 102000043168 TGF-beta family Human genes 0.000 description 4
• 108091085018 TGF-beta family Proteins 0.000 description 4
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
• 208000026062 Tissue disease Diseases 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 230000008468 bone growth Effects 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 239000001506 calcium phosphate Substances 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
• 229960001231 choline Drugs 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000004020 conductor Substances 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 210000002257 embryonic structure Anatomy 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 239000003862 glucocorticoid Substances 0.000 description 4
• 235000013922 glutamic acid Nutrition 0.000 description 4
• 239000004220 glutamic acid Substances 0.000 description 4
• 229940088597 hormone Drugs 0.000 description 4
• 239000005556 hormone Substances 0.000 description 4
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 230000002209 hydrophobic effect Effects 0.000 description 4
• 102000018358 immunoglobulin Human genes 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 210000003716 mesoderm Anatomy 0.000 description 4
• 208000030159 metabolic disease Diseases 0.000 description 4
• 210000002161 motor neuron Anatomy 0.000 description 4
• 210000003098 myoblast Anatomy 0.000 description 4
• 208000015122 neurodegenerative disease Diseases 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 201000008482 osteoarthritis Diseases 0.000 description 4
• 230000002188 osteogenic effect Effects 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 230000035899 viability Effects 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 230000004584 weight gain Effects 0.000 description 4
• 235000019786 weight gain Nutrition 0.000 description 4
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 102000018918 Activin Receptors Human genes 0.000 description 3
• 108010052946 Activin Receptors Proteins 0.000 description 3
• 102220556625 Acyl-coenzyme A thioesterase 11_K55A_mutation Human genes 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 208000000103 Anorexia Nervosa Diseases 0.000 description 3
• 206010003694 Atrophy Diseases 0.000 description 3
• 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 3
• 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 241000699802 Cricetulus griseus Species 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• 102220575187 Egl nine homolog 1_F82A_mutation Human genes 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000029725 Metabolic bone disease Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000021642 Muscular disease Diseases 0.000 description 3
• 102000003505 Myosin Human genes 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 102000044547 Nodal Human genes 0.000 description 3
• 108700024442 Nodal Proteins 0.000 description 3
• 208000011623 Obstructive Lung disease Diseases 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 102220495689 Putative uncharacterized protein FLJ43944_R40A_mutation Human genes 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 108700008625 Reporter Genes Proteins 0.000 description 3
• 241000714474 Rous sarcoma virus Species 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 208000010399 Wasting Syndrome Diseases 0.000 description 3
• 230000011759 adipose tissue development Effects 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 230000003042 antagnostic effect Effects 0.000 description 3
• 210000000628 antibody-producing cell Anatomy 0.000 description 3
• 230000037444 atrophy Effects 0.000 description 3
• 239000000440 bentonite Substances 0.000 description 3
• 229910000278 bentonite Inorganic materials 0.000 description 3
• 238000004166 bioassay Methods 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 238000001246 colloidal dispersion Methods 0.000 description 3
• 230000009918 complex formation Effects 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 238000009396 hybridization Methods 0.000 description 3
• 125000001165 hydrophobic group Chemical group 0.000 description 3
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000005462 in vivo assay Methods 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 230000000869 mutational effect Effects 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 239000006072 paste Substances 0.000 description 3
• 210000002976 pectoralis muscle Anatomy 0.000 description 3
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 229920002704 polyhistidine Polymers 0.000 description 3
• 230000002028 premature Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 230000017854 proteolysis Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 238000007423 screening assay Methods 0.000 description 3
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 229960000187 tissue plasminogen activator Drugs 0.000 description 3
• 230000017423 tissue regeneration Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 210000004881 tumor cell Anatomy 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• 208000037415 AIDS wasting syndrome Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 241000701822 Bovine papillomavirus Species 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 229920001268 Cholestyramine Polymers 0.000 description 2
• 102220578645 Chorion-specific transcription factor GCMb_N65A_mutation Human genes 0.000 description 2
• 229920002911 Colestipol Polymers 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 102100034239 Emerin Human genes 0.000 description 2
• 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 2
• 108091006020 Fc-tagged proteins Proteins 0.000 description 2
• 102100029379 Follistatin-related protein 3 Human genes 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 208000002705 Glucose Intolerance Diseases 0.000 description 2
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
• 208000003577 HIV wasting syndrome Diseases 0.000 description 2
• 241000713858 Harvey murine sarcoma virus Species 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 101001062529 Homo sapiens Follistatin-related protein 3 Proteins 0.000 description 2
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 description 2
• 241000713869 Moloney murine leukemia virus Species 0.000 description 2
• 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 2
• 208000010428 Muscle Weakness Diseases 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• 108010021466 Mutant Proteins Proteins 0.000 description 2
• 102000008300 Mutant Proteins Human genes 0.000 description 2
• 102100038380 Myogenic factor 5 Human genes 0.000 description 2
• 101710099061 Myogenic factor 5 Proteins 0.000 description 2
• 102220610729 Myogenic factor 5_L79P_mutation Human genes 0.000 description 2
• 206010068871 Myotonic dystrophy Diseases 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 230000004989 O-glycosylation Effects 0.000 description 2
• 102220567352 Ornithine decarboxylase antizyme 1_K74F_mutation Human genes 0.000 description 2
• 206010049088 Osteopenia Diseases 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 102220633854 PRKCA-binding protein_D80A_mutation Human genes 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
• 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 2
• 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102220577876 Poly(rC)-binding protein 1_W78A_mutation Human genes 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 102220469872 Protein argonaute-3_E37A_mutation Human genes 0.000 description 2
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
• 102000007374 Smad Proteins Human genes 0.000 description 2
• 108010007945 Smad Proteins Proteins 0.000 description 2
• 102000013275 Somatomedins Human genes 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
• 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 102000000523 Type II Activin Receptors Human genes 0.000 description 2
• 108010041546 Type II Activin Receptors Proteins 0.000 description 2
• 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
• 102220469729 Voltage-dependent L-type calcium channel subunit beta-2_D54K_mutation Human genes 0.000 description 2
• 102220479829 Voltage-dependent L-type calcium channel subunit beta-2_R56K_mutation Human genes 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 210000001766 X chromosome Anatomy 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 108010023079 activin B Proteins 0.000 description 2
• 108010057453 activin receptor type II-B Proteins 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 150000001409 amidines Chemical class 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000007910 cell fusion Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 201000006815 congenital muscular dystrophy Diseases 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 238000002316 cosmetic surgery Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 230000022811 deglycosylation Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 201000009338 distal myopathy Diseases 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
• 239000003205 fragrance Substances 0.000 description 2
• 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 230000002710 gonadal effect Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• 239000000185 hemagglutinin Substances 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 239000000710 homodimer Substances 0.000 description 2
• 229960000890 hydrocortisone Drugs 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 235000001705 insufficient nutrition Nutrition 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 230000009437 off-target effect Effects 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 230000002138 osteoinductive effect Effects 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 229940111202 pepsin Drugs 0.000 description 2
• 208000028169 periodontal disease Diseases 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 239000004626 polylactic acid Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 102000054765 polymorphisms of proteins Human genes 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 201000009104 prediabetes syndrome Diseases 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 230000007026 protein scission Effects 0.000 description 2
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 238000003571 reporter gene assay Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 102220005147 rs34173382 Human genes 0.000 description 2
• 102200158858 rs34435255 Human genes 0.000 description 2
• 102200089383 rs57977969 Human genes 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 208000001076 sarcopenia Diseases 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 235000000891 standard diet Nutrition 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 239000005495 thyroid hormone Substances 0.000 description 2
• 229940036555 thyroid hormone Drugs 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 230000005030 transcription termination Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 102000035160 transmembrane proteins Human genes 0.000 description 2
• 108091005703 transmembrane proteins Proteins 0.000 description 2
• 229940078499 tricalcium phosphate Drugs 0.000 description 2
• 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
• 235000019731 tricalcium phosphate Nutrition 0.000 description 2
• 238000005533 tritiation Methods 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 229960004295 valine Drugs 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
• SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
• AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
• CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 102100034111 Activin receptor type-1 Human genes 0.000 description 1
• 102100034134 Activin receptor type-1B Human genes 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 241000256836 Apis Species 0.000 description 1
• 241000256844 Apis mellifera Species 0.000 description 1
• 244000186140 Asperula odorata Species 0.000 description 1
• 241000714235 Avian retrovirus Species 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
• 241001147386 Bos sp. Species 0.000 description 1
• 101000937267 Bos taurus Activin receptor type-2B Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• XRYKMKMQJBOVES-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=O.C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC=O.C1=CC=CC=C1 XRYKMKMQJBOVES-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241000202252 Cerberus Species 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 208000003044 Closed Fractures Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 102000004420 Creatine Kinase Human genes 0.000 description 1
• 108010042126 Creatine kinase Proteins 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 108010074864 Factor XI Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 101150050927 Fcgrt gene Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 101710195101 Flagellar filament outer layer protein Proteins 0.000 description 1
• 102000016970 Follistatin Human genes 0.000 description 1
• 108010014612 Follistatin Proteins 0.000 description 1
• 108010012820 Follistatin-Related Proteins Proteins 0.000 description 1
• 102000019203 Follistatin-Related Proteins Human genes 0.000 description 1
• 235000008526 Galium odoratum Nutrition 0.000 description 1
• 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
• 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
• 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 1
• 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000009151 Luteinizing Hormone Human genes 0.000 description 1
• 108010073521 Luteinizing Hormone Proteins 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 206010025476 Malabsorption Diseases 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010038049 Mating Factor Proteins 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102100026632 Mimecan Human genes 0.000 description 1
• 208000034819 Mobility Limitation Diseases 0.000 description 1
• 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
• 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 101150118570 Msx2 gene Proteins 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• CMSYVPIXXGNYEG-KEWYIRBNSA-N N'-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetohydrazide Chemical compound CC(=O)NN[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O CMSYVPIXXGNYEG-KEWYIRBNSA-N 0.000 description 1
• CMSYVPIXXGNYEG-RTRLPJTCSA-N N'-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetohydrazide Chemical compound CC(=O)NN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CMSYVPIXXGNYEG-RTRLPJTCSA-N 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 208000002565 Open Fractures Diseases 0.000 description 1
• 239000004235 Orange GGN Substances 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 102000004067 Osteocalcin Human genes 0.000 description 1
• 108090000573 Osteocalcin Proteins 0.000 description 1
• 101800002327 Osteoinductive factor Proteins 0.000 description 1
• 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 101150012394 PHO5 gene Proteins 0.000 description 1
• 102000000536 PPAR gamma Human genes 0.000 description 1
• 108091008767 PPARγ2 Proteins 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 241000700162 Rattus sp. Species 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 108700013394 SOD1 G93A Proteins 0.000 description 1
• 238000011831 SOD1-G93A transgenic mouse Methods 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 241000282896 Sus sp. Species 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 108090001109 Thermolysin Proteins 0.000 description 1
• 102100036407 Thioredoxin Human genes 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 241000269360 Xenopus sp. Species 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
• 150000004645 aluminates Chemical class 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 229940069428 antacid Drugs 0.000 description 1
• 239000003159 antacid agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000002788 anti-peptide Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 230000009831 antigen interaction Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 239000000823 artificial membrane Substances 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000000022 bacteriostatic agent Substances 0.000 description 1
• 229940125717 barbiturate Drugs 0.000 description 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000003462 bioceramic Substances 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000005312 bioglass Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000033558 biomineral tissue development Effects 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000002449 bone cell Anatomy 0.000 description 1
• 230000014461 bone development Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 230000018678 bone mineralization Effects 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 230000021523 carboxylation Effects 0.000 description 1
• 238000006473 carboxylation reaction Methods 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000003321 cartilage cell Anatomy 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 239000000919 ceramic Substances 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
• 229940097479 colestid Drugs 0.000 description 1
• GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
• 229960002604 colestipol Drugs 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 208000012696 congenital leptin deficiency Diseases 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000005115 demineralization Methods 0.000 description 1
• 230000002328 demineralizing effect Effects 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000000741 diarrhetic effect Effects 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000018823 dietary intake Nutrition 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 229940064790 dilantin Drugs 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• HBNBMOGARBJBHS-UHFFFAOYSA-N dimethylarsane Chemical compound C[AsH]C HBNBMOGARBJBHS-UHFFFAOYSA-N 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000004821 effect on bone Effects 0.000 description 1
• 230000002828 effect on organs or tissue Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 230000001700 effect on tissue Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 210000001900 endoderm Anatomy 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 230000009786 epithelial differentiation Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 150000002169 ethanolamines Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 108091006047 fluorescent proteins Proteins 0.000 description 1
• 102000034287 fluorescent proteins Human genes 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 210000003194 forelimb Anatomy 0.000 description 1
• 208000020694 gallbladder disease Diseases 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 101150004578 gdf-8 gene Proteins 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 208000024693 gingival disease Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 150000002333 glycines Chemical class 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• 238000011540 hip replacement Methods 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 239000000960 hypophysis hormone Substances 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000012308 immunohistochemistry method Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
• 210000000982 limb bud Anatomy 0.000 description 1
• 230000006517 limb development Effects 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 230000004777 loss-of-function mutation Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 229940040129 luteinizing hormone Drugs 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 235000020938 metabolic status Nutrition 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000012900 molecular simulation Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 208000001022 morbid obesity Diseases 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 238000001964 muscle biopsy Methods 0.000 description 1
• 230000009753 muscle formation Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229940063121 neoral Drugs 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000004766 neurogenesis Effects 0.000 description 1
• 208000013315 neuromuscular junction disease Diseases 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 235000006286 nutrient intake Nutrition 0.000 description 1
• 210000001706 olfactory mucosa Anatomy 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000000849 parathyroid Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000009589 pathological growth Effects 0.000 description 1
• 238000000059 patterning Methods 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 125000001151 peptidyl group Chemical group 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 210000000229 preadipocyte Anatomy 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000009430 psychological distress Effects 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 229940073095 questran Drugs 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 235000018770 reduced food intake Nutrition 0.000 description 1
• 230000007261 regionalization Effects 0.000 description 1
• 201000010384 renal tubular acidosis Diseases 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 210000003019 respiratory muscle Anatomy 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 229940061969 rheumatrex Drugs 0.000 description 1
• 102220125997 rs141863326 Human genes 0.000 description 1
• 102220288227 rs141863326 Human genes 0.000 description 1
• 102220140258 rs146572379 Human genes 0.000 description 1
• 102220036189 rs273585616 Human genes 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 229940063122 sandimmune Drugs 0.000 description 1
• 230000000276 sedentary effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000036301 sexual development Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 230000022379 skeletal muscle tissue development Effects 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 210000003594 spinal ganglia Anatomy 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 231100000967 thyroidotoxicity Toxicity 0.000 description 1
• 229940098465 tincture Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000001256 tonic effect Effects 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 238000003160 two-hybrid assay Methods 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 229940033942 zoladex Drugs 0.000 description 1